Skip to main content
. 2023 Nov 10;11(1):e200179. doi: 10.1212/NXI.0000000000200179

Figure 2. Total Number of Studies Which Administered (Dark Gray) and Found Impairment in (Light Gray) Each Test in Samples of Anti-LGI-1 AE (A), Anti-NMDA-R AE (B), and AE Anti-CASPR2, Anti-GABAB-R, Anti-GAD65 AE (C) Patients and Results Pooled Across Samples (D).

Figure 2

Neuropsychological tests only included in 1 study were removed from figures.